Physician profile
Anna K Schuler
NPI 1609938133
$4,343.51
in general payments reported to CMS, 2019-2025
26 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $111 · 2021: $227 · 2022: $694 · 2023: $385 · 2024: $460 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $39.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.19 |
| Education | $39.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $605.62 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $474.56 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $447.56 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $395.44 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $247.97 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $245.46 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $228.15 | 2019-2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $201.31 | 2019-2024 | Velphoro |
| Akebia Therapeutics INC | $189.24 | 2022-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $189.00 | 2025 | |
| Aurinia Pharma U.S., INC. | $153.47 | 2021-2025 | Lupkynis |
| Daiichi Sankyo INC. | $138.55 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $127.31 | 2022-2025 | Acthar, Terlivaz |
| Baxter Healthcare | $122.78 | 2019-2022 | |
| Vifor Pharma, INC. | $113.89 | 2019-2024 | Veltassa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $62.65 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $60.53 | 2021-2025 | Shingrix |
| Ardelyx, INC. | $60.04 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.91 | 2025 | |
| Horizon Therapeutics Plc | $49.98 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $44.59 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.54 | 2024-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $30.95 | 2021 | |
| Shield Therapeutics INC | $24.92 | 2025 | |
| Scpharmaceuticals INC. | $17.53 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Schuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.